title: Coronary artery disease, cerebral non-fatal ischemic stroke in retinal vein occlusion: an 8-yr follow-up.
abstract: Forty-five consecutive subjects (26M, 19F; mean age 54 ± 14 yrs) with a diagnosed retinal vein occlusion (RVO), were followed-up for 8 yrs. As many as 145 sex-age- and blood pressure-matched individuals (78M, 67F; mean age 54.4 ± 13.5 yrs), that did not experience any vascular event, served as controls. At the time of the RVO, controls and subjects did not differ as to hypercholesterolemia, hypertrigliceridemia, diabetes mellitus, smoking habits, inherited/acquired thrombophilia. At the follow-up completion, they differed as to statin consumption (p = 0.016). During the 8-yrs follow-up, in the control population, 11 out of 145 (7.6%) subjects had experienced a major vascular event (8 coronary artery disease; 3 cerebral non-fatal ischemic stroke). In contrast, of the 45 subjects with a history of RVO, as many as 10 (22.2%) had experienced a major vascular event: 4 coronary artery disease; 4 cerebral non-fatal ischemic stroke; 2 cardiovascular + cerebrovascular event (p = 0.012). A prolonged antiplatelet treatment, prior to the major vascular event, was found in 5/45 cases (11.1%) vs 23/145 (15.9%) controls (p = 0.63). In contrast, a long-lasting administration of anti-hypertensive drugs, to achieve a control of blood pressure, was found in 83.4% of controls and only in 46.7% of cases (p < 0.0001). In conclusion, in a 8-yr follow-up, coronary artery disease and/or non-fatal ischemic stroke were more common in subjects with a history of RVO than in a large setting of subjects comparable for cardiovascular risk factors. These data also argue for RVO as a vascular disease in which aggressive anti-hypertensive therapy to prevent stroke and/or myocardial infarction is needed.
authors.affiliation: Dept. of Clinical and Experimental Medicine, Regional Reference Centre for Coagulation Disease, Federico II University, Via Pansini 5, Naples, Italy. mirdica@hotmail.com
authors.forename: M Di
authors.initials: MD
authors.lastname: Capua
authors.forename: M N D Di
authors.initials: MN
authors.lastname: Minno
authors.forename: A
authors.initials: A
authors.lastname: Guida
authors.forename: M
authors.initials: M
authors.lastname: Loffredo
authors.forename: C
authors.initials: C
authors.lastname: Cuccaro
authors.forename: A
authors.initials: A
authors.lastname: Coppola
authors.forename: R
authors.initials: R
authors.lastname: Izzo
authors.forename: N Macarone
authors.initials: NM
authors.lastname: Palmieri
authors.forename: A
authors.initials: A
authors.lastname: Crispo
authors.forename: A M
authors.initials: AM
authors.lastname: Cerbone
authors.forename: G Di
authors.initials: GD
authors.lastname: Minno
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage; D003324:Coronary Artery Disease / Q000150:complications / Q000503:physiopathology* / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000503:physiopathology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D012307:Risk Factors; D020521:Stroke / Q000503:physiopathology / Q000517:prevention & control*
chemical_list: D000959:Antihypertensive Agents; D010975:Platelet Aggregation Inhibitors